Overview

Neuropathic Pain Management Market Dynamics:

Neuropathic pain is a chronic pain condition caused owing to infection, trauma and other such dysfunctional systems in the nerves. Primary neuropathic pain syndromes include postherpetic neuralgia, painful neuropathy, painful traumatic mononeuropathy, central pain syndromes, complex regional pain syndrome and postsurgical pain syndromes. Anticonvulsants, antidepressants like tricyclic antidepressants and anaesthetics are generally prescribed for neuropathic pain. Furthermore, antidepressants like nortriptyline and amitriptyline are primarily used for managing neuropathic pain. Additionally, the growing prevalence of chronic diseases like diabetes and cancer shall bolster the neuropathic pain management market growth. However, a dearth of awareness pertaining to the implementation of the procedure in underdeveloped regions shall impede the proliferation of the market. Conversely, rise in the number of pain centres shall boost the augmentation of the market.

Neuropathic Pain Management Market Segmentation:

By Drug Class
•    Tricyclic Antidepressants
•    Anticonvulsants
•    SNRIs
•    Capsaicin Cream
•    Local Anaesthesia
•    Opioids
•    Steroids
•    Others
By Indication
•    Diabetic Neuropathy
•    Trigeminal Neuralgia 
•    Post-Herpetic Neuralgia
•    Chemotherapy-Induced Peripheral Neurotherapy
•    Others
By Distribution Channel
•    Retail Pharmacies
•    Hospital Pharmacies
•    Online Pharmacies
By Region
•    North America
•    Europe 
•    Asia Pacific
•    Latin America
•    Middle East & Africa

The market is categorised into drug class, indication, distribution channel and region. The drug class segment is classified into tricyclic antidepressants, anticonvulsants, SNRIs, capsaicin cream, local anaesthesia, opioids, steroids and others. The tricyclic antidepressants segment is predicted to hold the largest neuropathic pain management market share during the forecasted timeframe. The indication segment is fragmented into diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others. The distribution channel segment is diversified into retail pharmacies, hospital pharmacies and online pharmacies. The hospital pharmacies segment is anticipated to lead the market owing to growing investments for hospitals in developed and underdeveloped nations. 

Regional Analysis:

The North America region is expected to dominate the market and this can be credited to increased disposable income, rising geriatric population, a strong presence of key market players in the region. 

Competitive Landscape:                            

The major players included are Pfizer Inc., Johnson & Johnson Services Inc., Depomed Inc., Bristol-Myers Squibb and Company, Sanofi S.A., Biogen Idec Inc., Eli Lily and Company, GlaxoSmithKline PLC, Baxter Healthcare Corporation.

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global neuropathic pain management market by drug class, by indication, by distribution channel and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers, and expansions

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
          1.1 Objectives of the Study 
          1.2 Market Definition 
           1.3 Market Scope 
                1.3.1 Years Considered for the Study
                1.3.2 Market Covered

1.4 Currency
1.5 Limitations 
1.6 Stakeholders 

2. Research Methodology 

2.1 Research Data 

2.1.1 Secondary Data

2.1.1.1 Key Data from Secondary Sources

2.1.2 Primary Data

2.1.2.1 Key Data from Primary Sources

2.2 Market Size Estimation 
2.3 Market Breakdown and Data Triangulation 
2.4 Assumptions for the Study  

3. Executive Summary

3.1 Market Outlook
3.2 Segment Outlook
3.3 Competitive Insights

4. Market Variables, Trends & Scope
           4.1 Market Lineage Outlook
           4.2 Penetration and Growth Prospect Mapping
           4.3 Industry Value Chain Analysis
           4.4 Cost Analysis Breakdown
           4.5 Technology Overview
           4.6 Regulatory Framework on Country Level

4.6.1 Reimbursement Framework
4.6.2 Standards and Compliances

5. Market Overview

5.1 Market Dynamics
                 5.1.1 Market Driver Analysis
                 5.1.2 Market Restraint Analysis
                 5.1.3 Industry Challenge            

6. Market Analysis tools

6.1 Industry Analysis - Porter’s
                     6.1.1 Supplier Power
                     6.1.2 Buyer Power
                     6.1.3 Substitution Threat
                     6.1.4 Threat from new entrants
                     6.1.5 Competitive Rivalry
6.2 Pestel Analysis
                     6.2.1 Political Landscape
                     6.2.2 Environmental Landscape
                     6.2.3 Social landscape
                     6.2.4 Technology landscape
                     6.2.5 Legal Landscape

7. Neuropathic Pain Management Market, By Drug Class Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)

7.1 Tricyclic Antidepressants
7.2 Anticonvulsants
7.3 SNRIs
7.4 Capsaicin Cream
7.5 Local Anaesthesia
7.6 Opioids
7.7 Steroids
7.8 Others

8. Neuropathic Pain Management Market, By Indication Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)

8.1 Diabetic Neuropathy
8.2 Trigeminal Neuralgia
8.3 Post-Herpetic Neuralgia
8.4 Chemotherapy-Induced Peripheral Neurotherapy
8.5 Others

9. Neuropathic Pain Management Market, By Distribution Channel Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)

9.1 Hospital Pharmacies
9.2 Online Pharmacies
9.3 Retail Pharmacies

10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
         10.1. Introduction
         10.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                10.2.1. U.S.
                10.2.2. Canada
                10.2.3. Mexico
                10.2.4 Rest of North America
         10.3 Market Size (USD Mn) Forecast for North America 2020-2027

11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
         11.1. Introduction
         11.2. Regional Market Trends
         11.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
                   11.3.1. Brazil
                   11.3.2. Uruguay
                   11.3.3 Argentina
                   11.3.4. Rest of Latin America
         11.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027

12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
         12.1. Introduction
         12.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
                12.2.1. Germany
                12.2.2. U.K
                12.2.3. France
                12.2.4. Italy
                12.2.5 Switzerland
                12.2.6. Spain
                12.2.7. Russia
                12.2.8. Poland
                12.2.9. Rest of Western Europe
           12.3 Market Size (US$ Mn) Forecast for Europe 2020-2027

13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          13.1 Introduction
          13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                 13.2.1 Japan
                 13.2.2 China
                 13.2.3 Singapore
                 13.2.4 Korea         
                 13.2.5 India
                 13.2.6 Australia and New Zealand
                 13.2.7 ASEAN
                 13.2.8 Rest of Asia Pacific
         13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027

14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          14.1 Introduction
          14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
              14.2.1 UAE
              14.2.2 South Africa
              14.2.3 Egypt
              14.2.4 Saudi Arabia
              14.2.5 Rest of MEA
    14.3 Market Size (US$ Mn) Forecast for MEA 2020-2027

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)

15.1 Pfizer Inc.
    15.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    15.1.2. Product Portfolio
    15.1.3. SWOT Analysis
    15.1.4. Financial Overview
    15.1.5. Strategic Overview
15.2 Johnson & Johnson Services Inc.
    15.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    15.2.2. Product Portfolio
    15.2.3. SWOT Analysis
    15.2.4. Financial Overview
    15.2.5. Strategic Overview
15.3 Depomed Inc.
    15.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    15.3.2. Product Portfolio
    15.3.3. SWOT Analysis
    15.3.4. Financial Overview
    15.3.5. Strategic Overview
15.4 Bristol-Myers Squibb and Company
    15.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    15.4.2. Product Portfolio
    15.4.3. SWOT Analysis
    15.4.4. Financial Overview
    15.4.5. Strategic Overview
15.5 Sanofi S.A.
    15.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    15.5.2. Product Portfolio
    15.5.3. SWOT Analysis
    15.5.4. Financial Overview
    15.5.5. Strategic Overview
15.6 Biogen Idec Inc.
    15.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    15.6.2. Product Portfolio
    15.6.3. SWOT Analysis
    15.6.4. Financial Overview
    15.6.5. Strategic Overview
15.7 Eli Lily and Company
    15.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    15.7.2. Product Portfolio
    15.7.3. SWOT Analysis
    15.7.4. Financial Overview
    15.7.5. Strategic Overview
15.8 Baxter Healthcare Corporation
    15.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    15.8.2. Product Portfolio
    15.8.3. SWOT Analysis
    15.8.4. Financial Overview
    15.8.5. Strategic Overview    
15.9 GlaxoSmithKline PLC
    15.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    15.9.2. Product Portfolio
    15.9.3. SWOT Analysis
    15.9.4. Financial Overview
    15.9.5. Strategic Overview

16 Impact of COVID-19

16.1. Positive influence on the healthcare industry
16.2. The financial disruption of the manufacturing sector
16.3. Impact of COVID-19 on emerging companies
16.4. Significant mandates in the healthcare regulations initiated by administrations
16.5. The overall economic slowdown of the developing and developed nations

17 Competitive Intelligence and Competitive Matrix

17.1 Competitive Intelligence
17.2 Competitive Matrix

18. Major Deals and Strategic Alliances Analysis

18.1 Joint ventures
18.2 Mergers and acquisitions
18.3 Licensing and partnerships 
18.4 Technology Collaborations
18.5 Strategic Divestments
18.6 Market Entry Strategies        

19. Relevant Case Studies and Latest News Updates    

20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics

Tables

Figures